325 related articles for article (PubMed ID: 22459918)
21. Quality of life and clinical factors in women with endometriosis, the role of dienogest vs EE/dienogest over time: a single-center study.
Maiorana A; Alfano P; Mercurio A; Marcantonio S; Minneci G; Incandela D; Audino P
Arch Gynecol Obstet; 2023 May; 307(5):1503-1512. PubMed ID: 36738318
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability.
La Torre F; Vannuccini S; Toscano F; Gallucci E; Orlandi G; Manzi V; Petraglia F
Gynecol Endocrinol; 2024 Dec; 40(1):2336121. PubMed ID: 38579790
[TBL] [Abstract][Full Text] [Related]
23. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
Hornstein MD; Surrey ES; Weisberg GW; Casino LA
Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of dienogest treatment of clinical symptoms of rectovaginal endometriosis.
Papíková Z; Hudeček R; Ventruba P; Szypulová M
Ceska Gynekol; 2019; 84(5):331-336. PubMed ID: 31826628
[TBL] [Abstract][Full Text] [Related]
25. Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study.
Lang J; Yu Q; Zhang S; Li H; Gude K; von Ludwig C; Ren X; Dong L
J Womens Health (Larchmt); 2018 Feb; 27(2):148-155. PubMed ID: 29083258
[TBL] [Abstract][Full Text] [Related]
26. Safety of Dienogest and Other Hormonal Treatments for Endometriosis in Real-World Clinical Practice (VIPOS): A Large Noninterventional Study.
Heinemann K; Imthurn B; Marions L; Gerlinger C; Becker K; Moehner S; Faustmann T
Adv Ther; 2020 May; 37(5):2528-2537. PubMed ID: 32301063
[TBL] [Abstract][Full Text] [Related]
27. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study.
Strowitzki T; Faustmann T; Gerlinger C; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2010 Aug; 151(2):193-8. PubMed ID: 20444534
[TBL] [Abstract][Full Text] [Related]
28. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis.
Köhler G; Faustmann TA; Gerlinger C; Seitz C; Mueck AO
Int J Gynaecol Obstet; 2010 Jan; 108(1):21-5. PubMed ID: 19819448
[TBL] [Abstract][Full Text] [Related]
29. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.
Pokrzywinski RM; Soliman AM; Chen J; Snabes MC; Coyne KS; Surrey ES; Taylor HS
Am J Obstet Gynecol; 2020 Jun; 222(6):592.e1-592.e10. PubMed ID: 31759891
[TBL] [Abstract][Full Text] [Related]
30. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain.
Kitawaki J; Kusuki I; Yamanaka K; Suganuma I
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):212-6. PubMed ID: 21474232
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
32. Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials.
Gerlinger C; Faustmann T; Hassall JJ; Seitz C
BMC Womens Health; 2012 Apr; 12():9. PubMed ID: 22515510
[TBL] [Abstract][Full Text] [Related]
33. Use of dienogest over 53 weeks for the treatment of endometriosis.
Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
[TBL] [Abstract][Full Text] [Related]
34. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice.
Römer T
Arch Gynecol Obstet; 2018 Oct; 298(4):747-753. PubMed ID: 30076546
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience.
Maiorana A; Incandela D; Parazzini F; Alio W; Mercurio A; Giambanco L; Alio L
Arch Gynecol Obstet; 2017 Sep; 296(3):429-433. PubMed ID: 28664483
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study.
Osuga Y; Hayashi K; Kanda S
Fertil Steril; 2020 Jan; 113(1):167-175. PubMed ID: 31727415
[TBL] [Abstract][Full Text] [Related]
37. Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents.
Ebert AD; Dong L; Merz M; Kirsch B; Francuski M; Böttcher B; Roman H; Suvitie P; Hlavackova O; Gude K; Seitz C
J Pediatr Adolesc Gynecol; 2017 Oct; 30(5):560-567. PubMed ID: 28189702
[TBL] [Abstract][Full Text] [Related]
38. Effect of Dienogest therapy on the size of the endometrioma.
Vignali M; Belloni GM; Pietropaolo G; Barbasetti Di Prun A; Barbera V; Angioni S; Pino I
Gynecol Endocrinol; 2020 Aug; 36(8):723-727. PubMed ID: 32065005
[TBL] [Abstract][Full Text] [Related]
39. Randomized study on the effectiveness of nomegestrol acetate plus 17β-estradiol oral contraceptive versus dienogest oral pill in women with suspected endometriosis‑associated chronic pelvic pain.
Caruso S; Cianci A; Iraci Sareri M; Panella M; Caruso G; Cianci S
BMC Womens Health; 2022 May; 22(1):146. PubMed ID: 35538479
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study.
Nirgianakis K; Vaineau C; Agliati L; McKinnon B; Gasparri ML; Mueller MD
Acta Obstet Gynecol Scand; 2021 Jan; 100(1):30-40. PubMed ID: 32767677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
